Plasma Prolactin and Growth Hormone Levels in Manic Patients Treated with Pimozide

1982 ◽  
Vol 140 (3) ◽  
pp. 274-279 ◽  
Author(s):  
J. C. Cookson ◽  
T. Silverstone ◽  
Lesley Rees
Keyword(s):  
Growth Hormone ◽  
Plasma Prolactin ◽  
Close Correspondence ◽  
Hormone Levels ◽  
Manic Patients

SummaryDuring two weeks' treatment of 11 manic patients with pimozide there was close correspondence between the timecourse of improvement in clinical ratings and the rise in plasma prolactin between the second and fourteenth day. There were no significant differences in growth hormone levels during the manic episodes compared to recovery. These findings are discussed in relation to the role of dopamine in the release of prolactin and growth hormone, and in the pathogenesis of mania.

Effects of Indomethacin and Prostaglandin Injections on Plasma Prolactin and Growth Hormone Levels in Rats*

Endocrinology ◽  
1978 ◽  
Vol 102 (2) ◽  
pp. 531-539 ◽  
Author(s):  
S. R. OJEDA ◽  
H. E. JAMESON ◽  
S. M. MCCANN
Keyword(s):  
Growth Hormone ◽  
Plasma Prolactin ◽  
Hormone Levels

Abstract 17449: Predictive Value of Growth Hormone Levels in Cardiogenic Shock Patients

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Priyanka Boettger ◽  
Linda Bingener ◽  
Michael Buerke
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Cardiogenic Shock ◽  
Rapid Decline ◽  
High Morbidity ◽  
Normal Range ◽  
Observational Period ◽  
Hormone Levels ◽  
Male Patients

Introduction: Despite improved supportive care, cardiogenic shock still has a significantly high mortality. Among many factors, multiple changes in the neuroendocrine system, are responsible for the high morbidity and mortality. Reduced circulating level of insuline-like growth factor and an elevated level of growth hormone are the reported characteristic findings early in the course of sepsis and. The role of insuline-like growth factor and growth hormone levels in patients with cardiogenic shock has not been described. Methods: The aim of this study was to evaluate the changes of growth hormone/ insuline-like growth factor 1 axis in patients with cardiogenic shock. Results: When admitted, the average GH value of the patient collective was 2.86 μg / l ± 0.78. The values of the majority of the patients (31/41 = 75.6%) were within the normal range. There we no differences among survivors and non-survivors over the 96h observational period. We did not observe differences between either elder and younger patients or female and male CS patients. On admission IGF-1 levels were 76.23 ± 5.67 μg/l (normal range 70– 270 μg/l) at the lower end of the normal range. Over the next 48-72 hours, the value dropped to 66.8 μg/l. However, the drop was not significant (p = 0.14). Non-survivors showed a more rapid decline compared to survivors which stayed within the normal range.Considering the subgroup analysis, it emerges that the average IGF-1 value of male patients remains above 70 μg/l and thus within the normal range, while the IGF-1 level of the female patients during the course which was up to 55.3 μg/l decreases in the course. Clearly female CS patients showed a steeper decline compared to the male patients. Further younger CS patients showed higher levels compared to patients above 70 years. Conclusion: There were no significant changes of growth hormone levels over time and we observed a decrease of insuline-like growth factor 1 in cardiogenic shock patients. In addition, in non-survivors we detected even lower levels of growth hormone and lower levels of insuline-like growth factor 1. We think that both growth hormone and insuline-like growth factor 1 may have l prognostic value to serve as a marker in cardiogenic shock.

The effects of partial opiate agonists on plasma prolactin and growth hormone levels in the rat

Life Sciences ◽  
1979 ◽  
Vol 25 (20) ◽  
pp. 1709-1715 ◽  
Author(s):  
E.L. Lien ◽  
A. Morrison ◽  
Wm. Dvonch
Keyword(s):  
Growth Hormone ◽  
Plasma Prolactin ◽  
Hormone Levels

scholarly journals Role of Cyber knife Radiosurgery in pituitary mass and improvement in growth hormone levels

2018 ◽  
Vol 9 (5) ◽  
Author(s):  
Kausar Saldera ◽  
Rubnawaz Baloch, ◽  
Naveed Ahmed ◽  
Tariq Mahmood ◽  
Shazia Kadri
Keyword(s):  
Growth Hormone ◽  
Pituitary Mass ◽  
Hormone Levels

Hypothalamic histamine, growth rate, plasma prolactin and growth hormone levels in rats with long-term portacaval anastomosis

1999 ◽  
Vol 48 (2) ◽  
pp. 81-85 ◽  
Author(s):  
V. Lozeva ◽  
E. Anttila ◽  
R. K. Tuominen ◽  
M. Hippeläinen ◽  
P. T. Männistö ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Rate ◽  
Portacaval Anastomosis ◽  
Plasma Prolactin ◽  
Hormone Levels ◽  
Hypothalamic Histamine

THE EFFECT OF THE PROGESTOGEN ETHYNODIOL DIACETATE ON GLUCOSE, INSULIN, AND GROWTH HORMONE AFTER SIX MONTHS TREATMENT

1972 ◽  
Vol 70 (2) ◽  
pp. 373-384 ◽  
Author(s):  
W. N. Spellacy ◽  
W. C. Buhi ◽  
S. A. Birk
Keyword(s):  
Growth Hormone ◽  
Blood Glucose ◽  
Plasma Insulin ◽  
Tolerance Test ◽  
Metabolic Effects ◽  
Oral Glucose ◽  
Hormone Levels ◽  
Glucose Levels ◽  
Ethynodiol Diacetate ◽  
Tolerance Curve

ABSTRACT Seventy-one women were treated with a daily dose of 0.25 mg of the progestogen ethynodiol diacetate. They were all tested with a three-hour oral glucose tolerance test before beginning the steroid and then again during the sixth month of use. Measurements were made of blood glucose and plasma insulin and growth hormone levels. There was a significant elevation of the blood glucose levels after steroid treatment as well as a deterioration in the tolerance curve in 12.9% of the women. The plasma insulin values were also elevated after drug treatment whereas the fasting ambulatory growth hormone levels did not significantly change. There was a significant association between the changes in glucose and insulin levels and the subject's age, control weight, or weight gain during treatment. The importance of considering the metabolic effects of the progestogen component of oral contraceptives is stressed.

Sign in / Sign up

Export Citation Format

Share Document